Çѵ¶
°æ¿µ±âȹ / Àλç(HR) / ¸¶ÄÉÆà / ¾à¹°°¨½Ã(PV) / »ç¾÷°³¹ß(BD) / MA / MSL / »ý»ê

¸ðÁýºÎ¹®

MSL(Medical Science Liaison) (½ÅÀÔ/°æ·Â)
°ø°í¸¶°¨ÀÏ
  • ä¿ë ½Ã±îÁö ¸ðÁý
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ/°æ·Â
Á÷¹«»ó¼¼ MSLÀº field-based medical force·Î¼­ ¾Æ·¡¿Í °°Àº ¿ªÇÒ°ú Ã¥ÀÓÀÌ ÀÖ½À´Ï´Ù.
  • Medical Thought Leader¿¡°Ô Á¦Ç°ÀÇ ¿Ã¹Ù¸¥ ÀÇÇÐÀû °¡Ä¡(value)¸¦ °úÇÐÀû ±Ù°Å¸¦ ¹ÙÅÁÀ¸·Î °´°ü/±ÕÇüÀÖ°Ô Àü´Þ, medical insightÀÇ ¼öÁý/°øÀ¯, ÀÇÇÐÀû Àü·« ¼ö¸³/½ÇÇà
  • Á¦Ç°ÀÇ Life cycle¿¡ °ÉÃÄ Scientific program(½ÉÆ÷Áö¾ö, ÀÚ¹®È¸ÀÇ)ÀÇ ±âȹ ¹× ½ÇÇà
  • Á¦Ç° ¶Ç´Â Áúȯ°ú °ü·ÃµÈ ÀÓ»ó ¿¬±¸¸¦ °ü·Ã ±ÔÁ¤¿¡ µû¶ó È¿À²ÀûÀ¸·Î °ü¸®ÇÏ°í Áö¿ø
  • °ü·Ã Á¦Ç° ¹× Áúȯ¿¡ ´ëÇÑ ÀÇÇÐ ±³À°À» °èȹÇÏ°í ½ÃÇà
Áö¿øÀÚ°Ý
  • ¾à»ç ȤÀº À¯°üÇаú (»ý¹°ÇÐ, »ý¸í°úÇÐ µî ÀÚ¿¬°úÇÐ ÇÐÀ§) Á¹¾÷ÀÚ
  • Á¦¾àȸ»ç ¶Ç´Â °ü·Ã ȸ»ç¿¡¼­ MSL °æ·Â ¿ì´ë
  • ÀÓ»ó½ÃÇè °á°ú ¹× ¿¬±¸ ³í¹®¿¡ ´ëÇÑ ÀÌÇصµ
  • Learning agility (»õ·Î¿î Áúȯ ¹× Á¦Ç°¿¡ ´ëÇÑ ÇнÀ ¼ø¹ß·Â)
  • Communication skill; °í°´°úÀÇ ÀÇ»ç¼ÒÅë ´É·Â ¹× °í°´ÁöÇâÀûÀÎ ¼ºÇâ
ÀÇ·á±â±â »ç¾÷ºÎ Field Service ÆÀ¿ø (½ÅÀÔ/°æ·Â)
°ø°í¸¶°¨ÀÏ
  • ä¿ë ½Ã±îÁö ¸ðÁý
±Ù¹«Áö
  • °æ±â ³²ºÎ ¹× Ãæûµµ Áö¿ª º´¿ø ´ã´ç
°æ·Â±¸ºÐ
  • ½ÅÀÔ/°æ·Â
Á÷¹«»ó¼¼
  1. º´¿ø ÀÇ·á±â±â ¼³Ä¡ ¹× »ç¿ëÀÚ ±³À°
    • ÀÇ·á Àåºñ ¹× ½Ã¼³ÀÇ Á¡°Ë ¹× ¼³Ä¡ ¼öÇà
    • ÁÖ±âÀû »ç¿ëÀÚ ±³À° ¹× Çǵå¹é º¸°í
    • °æ±â ³²ºÎ ¹× Ãæûµµ Áö¿ª º´¿ø ´ã´ç
  2. ¼³Ä¡µÈ ÀåºñÀÇ À¯Áö º¸¼ö È°µ¿
    • °Å·¡Ã³ Àåºñ¿¡ ´ëÇÑ ÁÖ±âÀû Maintenance È°µ¿
    • ÁÖ¿ä °Å·¡Ã³ ¹æ¹® ¹× ¾÷¹« ó¸®
  3. Troubleshooting 页    • °í°´ claim ó¸®
    • troubleshooting ó¸® ¹× ÇöȲ ¾÷µ¥ÀÌÆ®
  4. ±â¼ú ±³À° ¹× upgrade
Áö¿øÀÚ°Ý
  • ÃÊ´ëÁ¹ ÀÌ»ó (ÀÇ·á/Àü±â/ÀüÀÚ/ÄÄÇ»ÅÍ °ü·Ã Çаú ¿ì´ë)
  • °ø¾÷ Ư¼ºÈ­°íµîÇб³ Á¹¾÷ÀÚ °¡´É
  • ½ÅÀÔ ¹× °æ·Â (°æ·ÂÀÇ °æ¿ì °ü·Ã ¾÷¹« 3³â ÀÌ»ó °æ·ÂÀÚ ¿ì´ë)
  • Àü±â ÀüÀÚ µî Àåºñ ¼­ºñ½º¿¡ ´ëÇÑ ÀÌÇØ, Àü±â ¹× ±â°è ºÐ¾ß ¹è°æ Áö½Ä
  • Software Service CS °æÇè ¿ì´ë
  • ±àÁ¤ÀûÀÌ°í ÁÖµµÀûÀÎ »ç°í
  • ¿îÀü¸éÇã Çʼö
  • TOEIC 700Á¡ ÀÌ»ó ¼ÒÁöÀÚ È¤Àº ÀÌ¿¡ »óÀÀÇÏ´Â °øÀξîÇмºÀû ¼ÒÁöÀÚ
  • °øÀξîÇмºÀûÀÌ ¾øÀ¸½Å °æ¿ì, ÀÚ»ç ÁÖ°üÀÇ ¸ðÀÇ ÅäÀÍÀ» ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
°æ¿µ±âȹ/Àü·« (½ÅÀÔ/°æ·Â)
°ø°í¸¶°¨ÀÏ
  • 2024/06/02
±Ù¹«Áö
  • Çѵ¶º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î)
°æ·Â±¸ºÐ
  • ½ÅÀÔ/°æ·Â
Á÷¹«»ó¼¼ ȸ»ç ºñÀü ´Þ¼ºÀ» À§ÇÑ Àü»ç ÇÁ·ÎÁ§Æ® ¿î¿µ, ´ë³»¿Ü »ê¾÷ȯ°æº¯È­ ºÐ¼® ¹× ÁßÀå±â °æ¿µÀü·« ¼ö¸³, »ç³» Á¶Á¤ ¹× ÄÚµð³×À̼ÇÀ» ÅëÇØ Àü»ç ¸ñÇ¥ ´Þ¼º¿¡ ±â¿©, °æ¿µÁø ÀÇ»ç°áÁ¤À» À§ÇÑ ÀÚ·á Áغñ, ÀÇ»ç°áÁ¤ ¼öÇà ¹× Á¶Á¤ ¿ªÇÒÀ» ¼öÇàÇÕ´Ï´Ù.
  • Àü»çÀûÀ¸·Î ÁøÇàµÇ´Â ÁÖ¿ä »ç¾÷Àü·«µéÀÇ È¿À²Àû ½ÇÇà Áö¿ø
  • °æ¿µºÐ¼®ÀÚ·á Áغñ ¹× °æ¿µÅë°è ¾÷¹«
  • ½Å±Ô ÇÁ·ÎÁ§Æ® ¼öÇà
  • Cross-functionalÇÑ ¾÷¹« Áö¿ø
  • °æ¿µÁøÀÌ °áÁ¤ÇÏ´Â ÁÖ¿ä »çÇ׵鿡 ´ëÇÑ ÈÄ¼Ó °ü¸®
Áö¿øÀÚ°Ý
  • 4³âÁ¦ ´ëÁ¹ ÀÌ»ó (Àü°ø¹«°ü, °æ¿µÇÐ/MBA µî °ü·Ã±³À° À̼öÀÚ ¼±È£)
  • ½ÅÀÔ ¹× °æ·Â 1³â ÀÌ»ó
  • °æ¿µ Àü¹Ý¿¡ ´ëÇÑ ÀÌÇØ¿Í °ü½É
  • ±âº»ÀûÀÎ °æ¿µÁöÇ¥ ¹× À繫ºÐ¼®¿¡ ´ëÇÑ ÀÌÇØ
  • Á¦¾à ¹× Healthcare Industry¿¡ ´ëÇÑ ÀÌÇØ
  • Àü»ç ÇÁ·ÎÁ§Æ® ±âȹ/°ü¸® ¶Ç´Â ±âȹ½Ç °æÇè ¿ì´ë
  • °èȹ¼ö¸³°ú ÇÁ·ÎÁ§Æ® °ü¸® ±âȹ·Â, ÃßÁø·Â, Àγ»·Â
  • ¹®Á¦ ÇØ°á´É·Â (Á¾ÇÕÀû, ³í¸®Àû, ºÐ¼®Àû, Àü·«Àû »ç°í)
  • ¿ø¸¸ÇÑ ´ëÀΰü°è, Ä¿¹Â´ÏÄÉÀÌ¼Ç ½ºÅ³
  • ±âº»ÀûÀÎ MS office È°¿ë ¹× ¿µ¾î ±¸»ç ´É·Â
Business Development ÆÀ¿ø
°ø°í¸¶°¨ÀÏ
  • 2024/06/02 (¿¬Àå)
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼ Licensing-In
  • ȸ»ç Àü·«¿¡ ºÎÇÕÇÏ´Â Æ÷Æ®Æú¸®¿À¿¡ µû¶ó Á¦Ç° ¹× »ç¾÷ ±âȸÀÇ °Ë»ö, °ËÅ並 ´ã´ç
    (ÀǾàÇ°, ÀÇ·á±â±â, ü¿ÜÁø´Ü¿ë ½Ã¾à ¹× ±â±â µî)
  • cross-functional team°ú ÇÔ²² due diligence¸¦ ÁÖ°üÇÏ¿© Æò°¡¸¦ ÁøÇà
  • Á¦Ç°, ½ÃÀå, finance modelingÀ» Æ÷ÇÔÇÑ »ç¾÷Á¦¾È¼­ °³¹ßÀ» Áö¿ø
  • µµÀÔ °áÁ¤½Ã ¾ç»ç°¡ win-winÇÒ ¼ö ÀÖµµ·Ï Çù»ó ¹× °è¾àÀ» Áö¿ø

Alliance Management
  • ÆÄÆ®³Ê»ç¿ÍÀÇ KPI ´Þ¼º ¹× the day-to-day ¾÷¹«¸¦ ´ã´ç.
  • ¹®Á¦°¡ ¿¹»óµÇ°Å³ª ¹ß»ý½Ã ÇØ°á ¹æ¾ÈÀ» Á¦½ÃÇÏ¸ç °ü·Ã ºÎ¼­ coordination
  • ³»¿ÜºÎ ÆÄÆ®³Ê¿Í Á¤±âÀû ¹ÌÆà µîÀ¸·Î ¿ìÈ£ÀûÀÎ ¾÷¹« ÇùÁ¶ °ü°è Á¶¼º.
Áö¿øÀÚ°Ý
  • ¾àÇÐ, »ý¸í°úÇÐ, »ý¹°ÇÐ, ÀÇ°øÇÐ °ü·Ã Àü°ø Çлç ÀÌ»ó, ¼®¹Ú»ç ¿ì´ë
  • °ü·Ã ¾÷¹« 3³â ÀÌ»óÀÎÀÚ·Î ¶óÀ̼¾½Ì/°³¹ß/BD ¾÷¹« 1³â ÀÌ»ó Çʼö
  • ÇコÄÉ¾î »ê¾÷¿¡ ´ëÇÑ ÀÌÇØ
  • LI/LOÀ» ÁøÇà °¡´ÉÇÑ Á¤µµÀÇ scientific, technical, business and financial Áö½Ä
  • ´Ù¾çÇÑ stakeholder¿Í Çù¾÷ÇÏ´Â ´É·Â
  • ¿ì¼öÇÑ ¼­¸é&±¸µÎ communication skill
  • »ç¾÷ ³íÀÇ°¡ °¡´ÉÇÒ Á¤µµÀÇ ¿Ü±¹¾î ´É·Â
  • Ã¥ÀÓ°¨ ÀÖ°í Àû±ØÀûÀÎ ¾÷¹« ŵµ
Market Access Specialist
°ø°í¸¶°¨ÀÏ
  • 2024/06/02 (¿¬Àå)
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼
  1. (ÁÖ¾÷¹«) ½Å¾àÀÇ ¾à°¡ ¹× ±Þ¿© °ü·Ã ¾÷¹« ¼öÇà
    • ¾àÁ¦±Þ¿© °áÁ¤½ÅûÀ» À§ÇÑ Value Dossier ÀÛ¼º
    • °æÁ¦¼ºÆò°¡ ±â¹Ý ¾à°¡°áÁ¤ ¹× local adaptation study management
    • °Ç°­º¸Çè½É»çÆò°¡¿ø, °Ç°­º¸Çè°ø´Ü°úÀÇ Æò°¡ ¹× Çù»ó
    • ¾à°¡ ½ÂÀÎ °úÁ¤À» À§ÇÑ ¼º°øÀû ÀÇ»ç¼ÒÅë°ú ºÎ¼­°£ »ó
  2. (ºÎ¾÷¹«) New pipeline ÀÇ ±¹³» Accessibility and Feasibility °ËÅä
    • µµÀÔ °ËÅä new productÀÇ ±¹³» °¡°Ý ¹× ±Þ¿© °¡´É¼º °ËÅä
  3. ½Å¾àÀÇ ÀûÁ¤¾à°¡ ¹× ±Þ¿©±âÁØ °áÁ¤À» À§ÇÑ Àü·« ¼ö¸³
    • ±¹³» ½ÃÀå, °æÀï ÇöȲ, Áúȯ Á¤º¸ µîÀ» ±â¹ÝÀ¸·Î ´ë»ó ȯÀÚ, Á¦Ç° Ư¡À» °í·ÁÇÑ Àü·« °ËÅä
  4. À§ÇèºÐ´ãÁ¦, °æÁ¦¼ºÆò°¡, °¡ÁßÆò±Õ°¡ »êÁ¤ ¹æ½Ä µî Àü·«Àû ½Ã³ª¸®¿ÀÀÇ °³¹ß
  5. CFT collaborative activities, Alignment of internal and external customers, Decision-making on best/base strategy
Áö¿øÀÚ°Ý
  • ¾àÇÐ, °£È£ÇÐ, º¸°ÇÇÐ(Á¤Ã¥, ¿ªÇÐ, Åë°è)À» Æ÷ÇÔÇÑ ¼®»çÇÐÀ§ ÀÌ»ó ¼ÒÁöÀÚ ¼±È£ ¶Ç´Â ÀÌ¿¡ ÁØÇÏ´Â ÀÚ
  • BD °ü·Ã ¾÷¹« °æÇèÀÚ ¿ì´ë
  • Market Access °ü·Ã ¾÷¹« °æ·ÂÀÚ (3³â ÀÌ»ó) - Region/HQ ¶Ç´Â ÆÄÆ®³Ê»ç¿Í Access & Pricing ³íÀÇ °¡´É
  • ½Å¾àÀÇ ±Þ¿© ¹× ¾à°¡°áÁ¤¿¡ ´ëÇÑ Á¦Ãâ ¹× Æò°¡ °ü·Ã full cycle °æÇèÀÚ ¿ì´ë
  • Strategic planning based on understanding of clinical evidence
  • Policy literacy - global and local
  • Stakeholder communication, English communication
  • Pharmacoeconomics
»ý»ê Á¦Á¶ ¹× Æ÷ÀåÀÛ¾÷ÀÚ
°ø°í¸¶°¨ÀÏ
  • 2024/06/02 (¿¬Àå)
±Ù¹«Áö
  • Çѵ¶Ä·ÆÛ½º (ÃæºÏ À½¼º)
°æ·Â±¸ºÐ
  • ½ÅÀÔ
Á÷¹«»ó¼¼
  • »ý»ê Á¦Á¶ ¹× Æ÷Àå ¾÷¹«
  • Ç¥ÁØ ÀÛ¾÷ÀýÂ÷ Áؼö ¹× ÇöÀåÁ¦Á¶, Æ÷Àå±ÔÁ¤ Áؼö
  • »ý»ê ¹× Æ÷Àå °øÁ¤ °³¼± È°µ¿.
Áö¿øÀÚ°Ý
  • °íµîÇб³ Á¹¾÷ ÀÌ»ó
  • ÁÖ°£ 2±³´ë ±Ù¹« °¡´ÉÇϽŠºÐ (¿ÀÀüÁ¶ 06:00~14:00 / ¿ÀÈÄÁ¶ 14:00~22:00)
  • MS Office »ç¿ë °¡´ÉÀÚ (¿¢¼¿/¿öµå)
  • ÆÀ¿öÅ©, Àû±ØÀûÀÎ Ä¿¹Â´ÏÄÉÀÌ¼Ç ½ºÅ³, ¼º½ÇÇÔ, Ã¥ÀÓ°¨
Life Science½Ç Marketing
°ø°í¸¶°¨ÀÏ
  • ä¿ë½Ã±îÁö ¸ðÁý (2Â÷ ¼­·ù¸¶°¨ 2024/04/28)
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼
  • ºê·£µå»ç (QIAGEN/ EPPENDORF/ Cellsafe/ Advanced Instrument) PO °ü¸®, ¸¶ÄÉÆà Àü·« ¼ö¸³, È«º¸ È°µ¿, Á¦Ç°±³À°
  • ºê·£µå»ç ¹× ¿µ¾÷»ç¿ø, ³»ºÎ À¯°üºÎ¼­¿ÍÀÇ ¿øÈ°ÇÑ Communication
  • ¸¶ÄÉÆà ¿¹»ê Planning, ÁýÇà ¹× °ü¸®
  • ½ÃÀå µ¿Çâ ¹× °æÀï»ç Á¤º¸¸¦ ÅëÇÑ ¸¶ÄÏ ºÐ¼®
  • ½Å±Ô ºê·£µå °³¹ß
Áö¿øÀÚ°Ý
  • 4³âÁ¦ ´ëÇÐ ÀÌ»ó (»ý¸í°øÇÐ, »ý¹°ÇÐ, ÀÇ»ý¸í°úÇаú µî °ü·Ã Àü°ø ¹× °ü·Ã ¼®»ç ¿ì´ë)
  • µ¿Á¾ ¾÷°è 4³â ÀÌ»ó °æ·Â º¸À¯ÀÚ
  • ¿Ü±¹°è ÆÄÆ®³Ê»ç¿Í ±âº»ÀûÀÎ ¿µ¾î ÀÇ»ç¼ÒÅë °¡´ÉÀÚ (¿µ¾î Speaking Test ÁøÇà)
  • ¿îÀü¸éÇã ÀÚ°ÝÁõ º¸À¯ÀÚ (2Á¾ º¸Åë ÀÌ»ó)
¸¸¼ºÁúȯ ´ç´¢/¼øȯ±â Marketing
°ø°í¸¶°¨ÀÏ
  • ä¿ë ½Ã±îÁö ¸ðÁý
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼ Àü¹®ÀǾàÇ° ´ç´¢ ¹× ¼øȯ±â ¿µ¿ªÀÇ Á¦Ç°À» ´ã´çÇÏ´Â ETC DCV Marketing
  1. Marketing planning & implementation
    • Resource allocation: Products mix against targets, A&P allocation efficiency
    • Long-term franchise strategy and planning: portfolio growth, alliance/business partnership
    • Timely report the supervisor according to objectives mutually agreed upon from year-to-year.
    • Take a ownership of specific brand performance measures
    • Perform developmental project base such as secondary market research, data analysis and etc.
    • Conduct a variety of administrative functions such as medical legal mark-ups, material development, clinical study utilization & field force communication, all essential to the day to day operation of the brand
  2. Key customer management :
    • Regular visit to target physicians
    • Provide physicians with updated highly scientific information on product & disease
    • Shape physicians¡¯ view on the disease and establish need for product
  3. Scientific program support
    • Develop key speakers to become strong advocates for the product & therapeutic class
    • Lead scientific initiatives to build clinical evident and implement medical programs
    • Search & provide updated articles on the product and develop key message
    • Deliver MR product training
  4. People, Capabilities, and Management:
    • Talent acquisition
    • Responsible for compliance with all legal requirements of company policies and ensure strict compliance.
Áö¿øÀÚ°Ý More than 3 years marketing experience : Must
  • Commercial experience of Diabetic disease / Cardiovascular field in pharmaceutical firm : preferred
  • Intermediate English communication/Presentation skill
  • High level communication skills
  • Proven project management skill (in the planning and new business case) : Understanding of P&L analysis
  • Creative and innovative approaches to problem solving
  • Strategic orientation
  • Pro-activity and willingness to initiative
  • Ability to foster and manage productive biz relationship with external stakeholders
¾à¹°°¨½Ã (Pharmacovigilance, PV)
°ø°í¸¶°¨ÀÏ
  • 2024/06/02
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ ¹× °æ·Â
Á÷¹«»ó¼¼
  • °³º°¾ÈÀü¼º»ç·Êº¸°í¼­ ÀÛ¼º ¹× Á¦Ãâ
  • ÆÄÆ®³Ê»ç communication
  • ¾à¹°°¨½Ã ±³À°
  • Ç°¸ñÇã°¡°»½Å ¾ÈÀü¼º ºÐ¼® º¸°í¼­ ÀÛ¼º
  • À§Çؼº°ü¸®°èȹ °³¹ß ¹× ¿î¿µ
  • ¾à¹°°¨½Ã SOP Á¦Á¤ ¹× °³Á¤
Áö¿øÀÚ°Ý
  • 4³âÁ¦ ´ëÇÐ Á¹¾÷ÀÚ ÀÌ»ó, ¾àÇÐ/°£È£ÇÐ/»ý¸í°øÇÐ µî °ü·Ã Àü°øÀÚ
  • ÀÓ»ó½ÃÇèÀ̳ª ¾à¹°°¨½Ã ¿µ¿ª 1³â ÀÌ»ó °æ·ÂÀÚ ¿ì´ë (½ÅÀÔ Áö¿ø °¡´É)
  • ¿µ¹® º¸°í¼­ ÀÛ¼º ¹× ¿µ¹® email communication °¡´ÉÇÑ ¾ð¾î ´É·Â
  • ¿ÀÇǽº ÇÁ·Î±×·¥, ÄÄÇ»ÅÍ »ç¿ë´É·Â, ÀÇ»ç¼ÒÅë ±â¼ú
HR Professional & Associate (ÀλçÆÀ)
°ø°í¸¶°¨ÀÏ
  • 2024/06/02
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ ¹× °æ·Â
Á÷¹«»ó¼¼
  • ÀÎ»ç ¾÷¹« Àü¹Ý¿¡ ´ëÇÑ ¿î¿µ (ä¿ë, ³ë¹«, ±ÙÅÂ, º¹¸®ÈÄ»ý, ´ë°ü µî)
  • Àλç Á¦µµÀÇ °³¼± ¹× ±âȹ
Áö¿øÀÚ°Ý ÀÚ°Ý ¹× Çʼö»çÇ×
  • ½ÅÀÔ ¹× °æ·Â
  • Çлç ÇÐÀ§ ÀÌ»ó (°æ¿µÇÐ, ¹ýÇÐ, ½É¸®ÇÐ µî °ü·Ã Àü°øÀÚ ¼±È£)
  • ½ÅÀÔ Áö¿øÀÚÀÇ °æ¿ì HR¿¡ ´ëÇÑ ³ôÀº °ü½ÉÀ» ¹ÙÅÁÀ¸·Î ´Ù¾çÇÑ ÀÎ»ç °ü·Ã °æÇè(ÀÚ°ÝÁõ, ÀÎÅÏ µî)ÀÌ ÀÖÀ¸½Å ºÐ
  • °æ·Â Áö¿øÀÚÀÇ °æ¿ì ÃÖ´ë 12³â ÀÌÇÏ ¹× 300ÀÎ ÀÌ»óÀÇ ±â¾÷¿¡¼­ ±Ù¹«ÇϽŠºÐ ¼±È£

¿ì´ë»çÇ×
  • ÁÖµµÀûÀÌ°í Ã¥ÀÓ°¨ ÀÖ´Â ¾÷¹« ŵµ
  • ³ôÀº À±¸® Àǽİú ¼¼ºÎ »çÇ׿¡ ÁÖÀÇÇϴ ŵµ
  • ¿ì¼öÇÑ ÀÇ»ç¼ÒÅë ´É·Â ¹× ´ëÀÎ °ü°è ´É·Â
  • ¹®Á¦ÇØ°á ¹× °¥µî Á¶Á¤ ´É·Â
  • ³í¸®Àû »ç°í·Â°ú µ¥ÀÌÅÍ ºÐ¼® ¹× º¸°í¼­ ÀÛ¼º ´É·Â
  • ³ëµ¿¹ý ¹× °ü·Ã ¹ý·ü¿¡ ´ëÇÑ °ü½É°ú Áö½Ä
  • ¿Ü±¹¾î(¿µ¾î) ´É·Â
[À°¾ÆÈÞÁ÷ ´ëü °è¾àÁ÷] Clinical Quality associate ¸ðÁý
°ø°í¸¶°¨ÀÏ
  • 2024/06/02
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼
  • »ç³» ÀÓ»ó½ÃÇè Á¾»çÀÚÀÇ ±³À° ½ÇÀû È®ÀÎ ¹× °ü¸®
  • ½Å±Ô Á÷¿øÀÇ OJT curriculum Áغñ ¹× °ü¸®
  • Á÷¿ø ±³À° ±â·ÏÀÇ °ü¸®, ³»/¿ÜºÎ ±³À° ÀÏÁ¤ °ü¸®
  • GCP/GVP °ü·Ã ¾÷¹« À§Å¹ ¾÷ü¿¡ ´ëÇÑ qualification Æò°¡ ¼öÇà ¶Ç´Â °ü¸® Áö¿ø
  • External partner audit ¹× º¸°Ç ´ç±¹ÀÇ inspection Áغñ
  • P&P/SOP, °ü·Ã ±ÔÁ¤, °èȹ¼­ À§¹Ý µî Monitor, CAPA ½ÇÇà follow-up
  • °ü·Ã ¹ý±Ô ¹× ȸ»ç policy¸¦ ÁؼöÇÏ´Â draft P&P ¹×/¶Ç´Â SOP °ü¸®
  • °ü·Ã ¹ý±Ô Á¦¡¤°³Á¤ ½Ã À¯°ü ºÎ¼­ÀÇ ¹ý±Ô ¿µÇâ Æò°¡ ÀýÂ÷ coordinating ¹× follow-up
Áö¿øÀÚ°Ý
  • ÀÇÇÐ, °£È£ÇÐ, ¾àÇÐ, ¼öÀÇÇÐ, º¸°ÇÇÐ µî »ý¸í°úÇÐ °ü·Ã 4³âÁ¦ ÀÌ»ó ´ëÇÐ Á¹¾÷
  • ÀÓ»ó½ÃÇè °ü·Ã ¾÷¹« ¶Ç´Â QA ¾÷¹« °æ·Â º¸À¯ÀÚ
  • GCP/GVP ±ÔÁ¤¿¡ ´ëÇÑ Àü¹® Áö½Ä ¹× ÀÌÇØ, ±âŸ ÀÇÇÐ ¿ë¾î ¹× ÀǾ࿡ °üÇÑ Áö½Ä ¹× ÀÌÇØ
  • ÁÁÀº ´ëÀÎ °ü°è, Ã¥ÀÓ°¨, ´Éµ¿ÀûÀÎ ¾÷¹« ó¸® ´É·Â, Time Management
  • °Ç°­ÇÔ, Àγ»½É, Good mind-control, ¼¼¹ÐÇÔ, ÀÚ±â°è¹ß¿¡ Àû±ØÀûÀΠŵµ µî

ÀüÇü´Ü°è


Á¦Ãâ¼­·ù

  • ÃÖÁ¾ÇÕ°Ý ÈÄ Á¦Ãâ